Related Experiment Video
Updated: Jun 20, 2026

A Semi-Automated and Reproducible Biological-Based Method to Quantify Calcium Deposition In Vitro
Published on: June 2, 2022
Sodium thiosulfate in the treatment of calcific uremic arteriolopathy
Georg Schlieper1, Vincent Brandenburg, Markus Ketteler
1Department of Nephrology and Clinical Immunology, RWTH Aachen University Hospital, Aachen, Germany. gschlieper@ukaachen.de
Insights
Calcific uremic arteriolopathy (CUA), a severe condition in dialysis patients, involves artery calcification. Sodium thiosulfate shows promise in case studies for treating CUA by preventing calcium phosphate precipitation.
Area of Science:
- Nephrology and Vascular Biology
- Mineral Metabolism and Calcification Pathways
Background:
- Calcific uremic arteriolopathy (CUA), or calciphylaxis, is a critical condition primarily affecting dialysis patients.
- Histopathology reveals medial calcification, fibrosis, and thrombosis in small arteries, often linked to bone and mineral metabolism disturbances.
Approach:
- Current treatments focus on normalizing mineral metabolism to reduce calcium phosphate oversaturation and precipitation.
- Sodium thiosulfate, a potential therapeutic, sequesters calcium ions, forming soluble complexes to inhibit calcium phosphate precipitation.
Key Points:
- This perspective reviews case reports and series on sodium thiosulfate for CUA, as randomized controlled trials are absent.
- Observed efficacy and a favorable short-term safety profile were noted in reported cases.
- The mechanism involves preventing calcium phosphate precipitation through calcium ion sequestration.
Conclusions:
- Sodium thiosulfate demonstrates potential as a treatment for calcific uremic arteriolopathy.
- Further large-scale clinical trials are essential to definitively establish its efficacy and long-term safety.
Abstract:
Calcific uremic arteriolopathy (CUA; also known as calciphylaxis) is a life-threatening condition observed mostly in patients on dialysis. The key histopathologic features of CUA include media calcification of small arteries, associated with endovascular fibrosis and thrombosis. Several risk factors for CUA are related to disturbances in bone and mineral metabolism; current treatments largely aim to normalize these disturbances by lowering serum calcium phosphate concentration and thereby preventing, or even reversing, calcium phosphate oversaturation, precipitation and, finally, calcification. Administration of sodium thiosulfate, which sequesters calcium ions to form highly soluble calcium thiosulfate complexes, can prevent calcium phosphate precipitation. As randomized controlled studies on sodium thiosulfate are lacking, this Perspectives article focuses on case reports and case series; in these reports the compound seemed to be effective and was not associated with serious short-term adverse events. Large clinical trials to evaluate the efficacy and long-term safety of sodium thiosulfate are clearly warranted.
Related Concept Videos
Urinary Tract Calculi IV: Nutrition Therapy and Prevention
Urinary Tract Calculi III: Medical Management
Antihypertensive Drugs: Thiazide-Class Diuretics
Urinary Tract Calculi II: Pathophysiology and Clinical Manifestations
Urinary Tract Calculi VI: Surgical Management
Urinary Tract Calculi V: Nursing Management
